Literature DB >> 26526299

A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy.

Kuljit Singh1,2, Mohammad Qutub1,3, Kristin Carson2, Benjamin Hibbert1, Christopher Glover1.   

Abstract

OBJECTIVE: Our objective was to perform an updated systematic review to compare the efficacy and short- and long-term mortality of surgical myectomy (SM) and alcohol septal ablation (ASA) by including most recent and largest cohort studies published in last few years.
BACKGROUND: SM and ASA are the two invasive strategies used to relieve left ventricular outflow tract obstruction (LVOTO) in patients with drug refractory symptomatic hypertrophic cardiomyopathy (HCM). In the absence of a randomized trial, we tried to compare the pros and cons of the two procedures using a systematic review and meta-analysis.
METHOD: A comprehensive search of three major databases was performed. We included original research studies comparing data on ASA and SM. Of 1,143 citations, 10 studies were included in the analysis.
RESULTS: A total of 805 patients underwent ASA and 1,019 underwent SM. Patients undergoing SM were younger (MD 6.3, P = 0.0001) and had higher reduction in the LVOT gradient (MD -9.56, P = 0.05). However, there was similar resolution of class III and IV symptoms between the two groups (P = 0.56). There was no difference in sudden cardiac death (SCD) (P = 0.93), short-term (P = 0.36), long-term all cause (P = 0.27), and long-term cardiac mortality (P = 0.58). Patients undergoing ASA had higher incidence of post procedure device implantation (OR 3.09, P < 0.00001).
CONCLUSION: No significant difference in symptom relief was noted between the two approaches. ASA was as safe a myectomy with regards to SCD, short-term, and long-term mortality.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  alcohol septal ablation; hypertrophic cardiomyopathy; septal myectomy

Mesh:

Substances:

Year:  2015        PMID: 26526299     DOI: 10.1002/ccd.26293

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  8 in total

Review 1.  Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published results.

Authors:  Angelos G Rigopoulos; Stefanos Sakellaropoulos; Muhammad Ali; Sophie Mavrogeni; Athanassios Manginas; Matthias Pauschinger; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

Review 2.  Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Marios Matiakis; Hannes Melnyk; Sophie Mavrogeni; Dionyssios Leftheriotis; Boris Bigalke; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

3.  Ultrasonic Cavitation-Enabled Treatment for Therapy of Hypertrophic Cardiomyopathy: Proof of Principle.

Authors:  Douglas L Miller; Xiaofang Lu; Chunyan Dou; Yiying I Zhu; Rachael Fuller; Kristina Fields; Mario L Fabiilli; Gabe E Owens; David Gordon; Oliver D Kripfgans
Journal:  Ultrasound Med Biol       Date:  2018-04-19       Impact factor: 2.998

Review 4.  Hypertrophic Obstructive Cardiomyopathy.

Authors:  Angelika Batzner; Hans-Joachim Schäfers; Konstantin V Borisov; Hubert Seggewiß
Journal:  Dtsch Arztebl Int       Date:  2019-01-25       Impact factor: 5.594

Review 5.  Review of Contemporary Invasive Treatment Approaches and Critical Appraisal of Guidelines on Hypertrophic Obstructive Cardiomyopathy: State-of-the-Art Review.

Authors:  Steven Lebowitz; Mariusz Kowalewski; Giuseppe Maria Raffa; Danny Chu; Matteo Greco; Caterina Gandolfo; Carmelo Mignosa; Roberto Lorusso; Piotr Suwalski; Michele Pilato
Journal:  J Clin Med       Date:  2022-06-14       Impact factor: 4.964

Review 6.  Obstructive Form of Hypertrophic Cardiomyopathy-Left Ventricular Outflow Tract Gradient: Novel Methods of Provocation, Monitoring of Biomarkers, and Recent Advances in the Treatment.

Authors:  Pawel Petkow Dimitrow; Renata Rajtar-Salwa
Journal:  Biomed Res Int       Date:  2016-05-10       Impact factor: 3.411

Review 7.  Alcohol septal ablation in hypertrophic cardiomyopathy.

Authors:  Juan José Santos Mateo; Juan R Gimeno
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

Review 8.  Update on hypertrophic cardiomyopathy and a guide to the guidelines.

Authors:  Srijita Sen-Chowdhry; Daniel Jacoby; James C Moon; William J McKenna
Journal:  Nat Rev Cardiol       Date:  2016-09-29       Impact factor: 32.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.